Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Glucocorticoid | 27 | 2019 | 117 | 7.280 |
Why?
|
Immediate-Early Proteins | 18 | 2014 | 164 | 3.820 |
Why?
|
Breast Neoplasms | 37 | 2021 | 2881 | 2.900 |
Why?
|
Mammary Neoplasms, Experimental | 12 | 2016 | 124 | 2.210 |
Why?
|
Receptors, Estrogen | 10 | 2021 | 382 | 1.900 |
Why?
|
Paclitaxel | 8 | 2016 | 460 | 1.780 |
Why?
|
Glucocorticoids | 7 | 2012 | 347 | 1.730 |
Why?
|
Mammary Glands, Animal | 11 | 2020 | 78 | 1.720 |
Why?
|
Dexamethasone | 11 | 2015 | 326 | 1.380 |
Why?
|
Adipose Tissue | 3 | 2016 | 240 | 1.270 |
Why?
|
Apoptosis | 17 | 2019 | 1678 | 1.270 |
Why?
|
Mifepristone | 6 | 2015 | 33 | 1.240 |
Why?
|
Triple Negative Breast Neoplasms | 4 | 2020 | 136 | 1.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 12 | 2019 | 1196 | 1.080 |
Why?
|
Epithelial Cells | 9 | 2018 | 662 | 1.040 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2017 | 74 | 0.950 |
Why?
|
Signal Transduction | 17 | 2018 | 3233 | 0.950 |
Why?
|
Cell Line, Tumor | 16 | 2019 | 2421 | 0.910 |
Why?
|
Social Isolation | 4 | 2013 | 67 | 0.900 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2016 | 46 | 0.860 |
Why?
|
Gene Expression Profiling | 7 | 2019 | 1381 | 0.800 |
Why?
|
Female | 63 | 2021 | 44405 | 0.800 |
Why?
|
Mastodynia | 1 | 2020 | 1 | 0.780 |
Why?
|
Breast Cyst | 1 | 2020 | 4 | 0.780 |
Why?
|
Oligonucleotide Array Sequence Analysis | 7 | 2014 | 689 | 0.740 |
Why?
|
Neoplasm Proteins | 3 | 2017 | 532 | 0.730 |
Why?
|
Estrogen Receptor alpha | 3 | 2015 | 144 | 0.730 |
Why?
|
Proteasome Endopeptidase Complex | 4 | 2008 | 99 | 0.700 |
Why?
|
Antineoplastic Agents, Phytogenic | 6 | 2013 | 276 | 0.690 |
Why?
|
Gene Expression Regulation | 4 | 2015 | 1917 | 0.690 |
Why?
|
Dual Specificity Phosphatase 1 | 5 | 2013 | 17 | 0.680 |
Why?
|
Animals | 43 | 2020 | 26518 | 0.670 |
Why?
|
Mice | 27 | 2020 | 11313 | 0.670 |
Why?
|
Adipocytes | 3 | 2015 | 155 | 0.660 |
Why?
|
Magnetic Resonance Imaging | 15 | 2019 | 3347 | 0.650 |
Why?
|
Ovarian Neoplasms | 3 | 2017 | 738 | 0.650 |
Why?
|
Cell Survival | 11 | 2018 | 966 | 0.630 |
Why?
|
Fatty Acids | 2 | 2018 | 129 | 0.620 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2015 | 45 | 0.610 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2021 | 589 | 0.590 |
Why?
|
Chromatin | 1 | 2019 | 378 | 0.580 |
Why?
|
Phosphoprotein Phosphatases | 3 | 2006 | 57 | 0.570 |
Why?
|
Humans | 65 | 2021 | 86281 | 0.570 |
Why?
|
Forkhead Transcription Factors | 2 | 2008 | 166 | 0.560 |
Why?
|
Ubiquitin | 2 | 2006 | 93 | 0.550 |
Why?
|
Phosphatidylinositol 3-Kinases | 6 | 2012 | 262 | 0.540 |
Why?
|
Subcutaneous Fat | 1 | 2015 | 18 | 0.540 |
Why?
|
Lysophospholipids | 1 | 2016 | 63 | 0.540 |
Why?
|
Triazoles | 1 | 2016 | 96 | 0.530 |
Why?
|
Immunohistochemistry | 9 | 2017 | 1752 | 0.520 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2014 | 28 | 0.500 |
Why?
|
Albumins | 1 | 2014 | 133 | 0.480 |
Why?
|
Antineoplastic Agents | 5 | 2018 | 2351 | 0.480 |
Why?
|
Cell Proliferation | 7 | 2019 | 1571 | 0.480 |
Why?
|
Hormone Antagonists | 1 | 2013 | 20 | 0.480 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2013 | 29 | 0.470 |
Why?
|
Nuclear Proteins | 3 | 2004 | 694 | 0.470 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2014 | 877 | 0.470 |
Why?
|
Mammary Neoplasms, Animal | 5 | 2020 | 54 | 0.470 |
Why?
|
Prostatic Neoplasms | 5 | 2021 | 1708 | 0.460 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 458 | 0.460 |
Why?
|
Antigens, Polyomavirus Transforming | 5 | 2015 | 47 | 0.460 |
Why?
|
Cell Cycle Proteins | 3 | 2004 | 388 | 0.460 |
Why?
|
Chelating Agents | 1 | 2013 | 69 | 0.460 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2014 | 318 | 0.450 |
Why?
|
Calcium Signaling | 1 | 2013 | 129 | 0.440 |
Why?
|
Pituitary-Adrenal System | 1 | 2012 | 64 | 0.440 |
Why?
|
Organometallic Compounds | 1 | 2013 | 132 | 0.440 |
Why?
|
Receptors, Adrenergic, beta | 1 | 2013 | 72 | 0.440 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 138 | 0.440 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2012 | 81 | 0.430 |
Why?
|
Neoplasms | 3 | 2021 | 2889 | 0.430 |
Why?
|
Breast | 8 | 2021 | 286 | 0.420 |
Why?
|
Mice, SCID | 4 | 2015 | 252 | 0.420 |
Why?
|
Multiprotein Complexes | 2 | 2012 | 94 | 0.410 |
Why?
|
Receptors, Progesterone | 3 | 2011 | 165 | 0.410 |
Why?
|
Receptors, Androgen | 6 | 2021 | 110 | 0.400 |
Why?
|
Inflammation | 2 | 2021 | 913 | 0.400 |
Why?
|
Up-Regulation | 2 | 2013 | 710 | 0.400 |
Why?
|
Stress, Psychological | 4 | 2021 | 313 | 0.400 |
Why?
|
Carcinoma | 2 | 2011 | 434 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2017 | 1305 | 0.380 |
Why?
|
RNA, Messenger | 9 | 2013 | 1975 | 0.370 |
Why?
|
Mutation | 4 | 2019 | 3952 | 0.370 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2015 | 2434 | 0.360 |
Why?
|
Mitochondria | 1 | 2013 | 535 | 0.360 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2006 | 222 | 0.360 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2021 | 427 | 0.360 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 111 | 0.360 |
Why?
|
Tumor Cells, Cultured | 7 | 2013 | 1040 | 0.350 |
Why?
|
Receptor, ErbB-2 | 3 | 2017 | 223 | 0.350 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2017 | 122 | 0.350 |
Why?
|
Carcinogenesis | 3 | 2021 | 194 | 0.340 |
Why?
|
Transcription, Genetic | 6 | 2019 | 1135 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 4 | 2003 | 189 | 0.340 |
Why?
|
Calcium | 1 | 2013 | 1148 | 0.330 |
Why?
|
Diet, High-Fat | 2 | 2020 | 113 | 0.330 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2008 | 47 | 0.320 |
Why?
|
Proteins | 2 | 2012 | 777 | 0.320 |
Why?
|
Cell Cycle | 2 | 2019 | 502 | 0.320 |
Why?
|
Protein Tyrosine Phosphatases | 2 | 2004 | 46 | 0.320 |
Why?
|
Mice, Transgenic | 10 | 2018 | 1537 | 0.310 |
Why?
|
Protein Binding | 4 | 2019 | 1454 | 0.310 |
Why?
|
Disease Progression | 8 | 2021 | 1531 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2005 | 321 | 0.300 |
Why?
|
Phosphorylation | 5 | 2012 | 1101 | 0.300 |
Why?
|
Biomarkers | 1 | 2013 | 1709 | 0.290 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2015 | 133 | 0.280 |
Why?
|
Blotting, Western | 4 | 2009 | 781 | 0.270 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2006 | 165 | 0.270 |
Why?
|
Gene Expression | 5 | 2016 | 1281 | 0.270 |
Why?
|
Transfection | 5 | 2008 | 895 | 0.270 |
Why?
|
Adult | 16 | 2020 | 25577 | 0.260 |
Why?
|
Disease Models, Animal | 6 | 2020 | 2227 | 0.260 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2004 | 380 | 0.260 |
Why?
|
Aged, 80 and over | 8 | 2017 | 6481 | 0.260 |
Why?
|
Prognosis | 10 | 2018 | 3669 | 0.260 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2015 | 156 | 0.260 |
Why?
|
Contrast Media | 3 | 2017 | 1076 | 0.250 |
Why?
|
Tamoxifen | 2 | 2003 | 167 | 0.240 |
Why?
|
Imaging, Three-Dimensional | 3 | 2020 | 579 | 0.240 |
Why?
|
MAP Kinase Signaling System | 1 | 2004 | 192 | 0.240 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2003 | 33 | 0.240 |
Why?
|
MCF-7 Cells | 2 | 2015 | 106 | 0.240 |
Why?
|
Models, Biological | 3 | 2008 | 1748 | 0.240 |
Why?
|
Middle Aged | 16 | 2021 | 24957 | 0.240 |
Why?
|
Biomarkers, Tumor | 4 | 2018 | 1461 | 0.240 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2016 | 272 | 0.240 |
Why?
|
Enzyme Activation | 4 | 2012 | 692 | 0.230 |
Why?
|
Caspase 3 | 2 | 2013 | 159 | 0.230 |
Why?
|
Aged | 15 | 2019 | 18353 | 0.230 |
Why?
|
Enhancer Elements, Genetic | 2 | 2019 | 266 | 0.230 |
Why?
|
COS Cells | 3 | 2008 | 166 | 0.220 |
Why?
|
Enzyme Induction | 3 | 2013 | 88 | 0.220 |
Why?
|
Ubiquitins | 1 | 2002 | 38 | 0.220 |
Why?
|
Cell Line | 7 | 2009 | 2466 | 0.210 |
Why?
|
Genomics | 2 | 2019 | 710 | 0.210 |
Why?
|
Estradiol | 1 | 2003 | 249 | 0.210 |
Why?
|
RNA, Small Interfering | 4 | 2018 | 547 | 0.210 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 2 | 2018 | 12 | 0.200 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2013 | 152 | 0.200 |
Why?
|
Sirolimus | 2 | 2012 | 169 | 0.190 |
Why?
|
Down-Regulation | 3 | 2008 | 504 | 0.190 |
Why?
|
Genes, myc | 1 | 2000 | 39 | 0.190 |
Why?
|
Cells, Cultured | 3 | 2015 | 2810 | 0.190 |
Why?
|
Simian virus 40 | 2 | 2015 | 35 | 0.190 |
Why?
|
Proto-Oncogene Proteins | 5 | 2004 | 645 | 0.190 |
Why?
|
Disease-Free Survival | 5 | 2017 | 1203 | 0.190 |
Why?
|
Transcription Factors | 2 | 2004 | 1555 | 0.180 |
Why?
|
Mammography | 2 | 2020 | 460 | 0.180 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2001 | 211 | 0.180 |
Why?
|
Arteries | 1 | 2020 | 174 | 0.180 |
Why?
|
Transplantation, Heterologous | 2 | 2013 | 363 | 0.170 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2012 | 150 | 0.170 |
Why?
|
Gadolinium DTPA | 2 | 2017 | 261 | 0.170 |
Why?
|
Random Allocation | 2 | 2018 | 332 | 0.170 |
Why?
|
Arabidopsis Proteins | 1 | 2000 | 137 | 0.160 |
Why?
|
Biopsy | 2 | 2020 | 1160 | 0.160 |
Why?
|
Dietary Sugars | 1 | 2018 | 8 | 0.160 |
Why?
|
Megestrol Acetate | 1 | 2017 | 10 | 0.160 |
Why?
|
Diet, Fat-Restricted | 1 | 2018 | 30 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2017 | 468 | 0.160 |
Why?
|
Magnetic Resonance Angiography | 1 | 2020 | 261 | 0.160 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 169 | 0.160 |
Why?
|
Feeding Behavior | 1 | 2020 | 324 | 0.150 |
Why?
|
Forkhead Box Protein O3 | 2 | 2008 | 20 | 0.150 |
Why?
|
Metabolome | 1 | 2017 | 47 | 0.150 |
Why?
|
Immunoenzyme Techniques | 2 | 2008 | 303 | 0.150 |
Why?
|
Small Molecule Libraries | 1 | 2017 | 61 | 0.150 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 25 | 0.150 |
Why?
|
Transcriptome | 2 | 2018 | 574 | 0.150 |
Why?
|
Dietary Fats | 1 | 2017 | 134 | 0.140 |
Why?
|
Neoplasm Invasiveness | 5 | 2020 | 551 | 0.140 |
Why?
|
Rats | 7 | 2018 | 3984 | 0.140 |
Why?
|
Interdisciplinary Communication | 2 | 2010 | 130 | 0.140 |
Why?
|
Algorithms | 1 | 2004 | 1828 | 0.140 |
Why?
|
Response Elements | 1 | 2016 | 63 | 0.140 |
Why?
|
Protein Processing, Post-Translational | 2 | 2012 | 371 | 0.140 |
Why?
|
Binding Sites | 2 | 2009 | 1098 | 0.140 |
Why?
|
Culture Media, Conditioned | 1 | 2016 | 104 | 0.140 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2017 | 105 | 0.130 |
Why?
|
Amino Acid Motifs | 2 | 2006 | 116 | 0.130 |
Why?
|
Luciferases | 2 | 2006 | 118 | 0.130 |
Why?
|
Embryo, Mammalian | 1 | 1995 | 207 | 0.130 |
Why?
|
Drug Synergism | 1 | 2016 | 303 | 0.130 |
Why?
|
Biomedical Research | 1 | 2019 | 375 | 0.130 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 53 | 0.130 |
Why?
|
Lymph Nodes | 2 | 2015 | 530 | 0.130 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2015 | 1200 | 0.130 |
Why?
|
Carcinoma, Lobular | 1 | 2015 | 80 | 0.130 |
Why?
|
Endoplasmic Reticulum | 2 | 2006 | 250 | 0.130 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 191 | 0.130 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2013 | 46 | 0.130 |
Why?
|
Coconut Oil | 1 | 2014 | 4 | 0.130 |
Why?
|
Plant Oils | 1 | 2014 | 9 | 0.130 |
Why?
|
Fibroblasts | 3 | 2006 | 729 | 0.120 |
Why?
|
Protein Phosphatase 1 | 2 | 2004 | 34 | 0.120 |
Why?
|
Cell Death | 1 | 2015 | 256 | 0.120 |
Why?
|
Caspase 7 | 1 | 2013 | 15 | 0.120 |
Why?
|
Mitochondrial Membranes | 1 | 2013 | 14 | 0.120 |
Why?
|
Caloric Tests | 1 | 2013 | 6 | 0.120 |
Why?
|
Lipogenesis | 1 | 2013 | 22 | 0.120 |
Why?
|
Genetic Testing | 1 | 2017 | 535 | 0.120 |
Why?
|
Cell Differentiation | 2 | 2018 | 1456 | 0.120 |
Why?
|
Necrosis | 1 | 2013 | 204 | 0.110 |
Why?
|
Healthcare Disparities | 1 | 2017 | 369 | 0.110 |
Why?
|
Leptin | 1 | 2013 | 105 | 0.110 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 391 | 0.110 |
Why?
|
Furans | 1 | 2012 | 16 | 0.110 |
Why?
|
Food | 1 | 2013 | 85 | 0.110 |
Why?
|
Mechanistic Target of Rapamycin Complex 2 | 1 | 2012 | 11 | 0.110 |
Why?
|
Enzyme Activators | 1 | 2012 | 14 | 0.110 |
Why?
|
Thapsigargin | 1 | 2012 | 55 | 0.110 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 29 | 0.110 |
Why?
|
Hypothalamus | 1 | 2012 | 79 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 376 | 0.110 |
Why?
|
Time Factors | 4 | 2012 | 5198 | 0.110 |
Why?
|
Neoplasm Staging | 3 | 2017 | 1932 | 0.110 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 853 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 329 | 0.100 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2011 | 40 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2012 | 182 | 0.100 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 124 | 0.100 |
Why?
|
bcl-X Protein | 3 | 2006 | 52 | 0.100 |
Why?
|
Chromones | 2 | 2008 | 28 | 0.100 |
Why?
|
Cyclins | 2 | 2004 | 82 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2004 | 74 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 339 | 0.100 |
Why?
|
Stress, Physiological | 2 | 2009 | 226 | 0.100 |
Why?
|
Morpholines | 2 | 2008 | 65 | 0.090 |
Why?
|
Promoter Regions, Genetic | 2 | 2018 | 937 | 0.090 |
Why?
|
Pyridines | 1 | 2012 | 309 | 0.090 |
Why?
|
Group Processes | 1 | 2010 | 31 | 0.090 |
Why?
|
Glucose | 1 | 2013 | 637 | 0.090 |
Why?
|
Community-Institutional Relations | 1 | 2010 | 29 | 0.090 |
Why?
|
Neoplasm Metastasis | 3 | 2017 | 1056 | 0.090 |
Why?
|
Models, Molecular | 1 | 2014 | 1284 | 0.090 |
Why?
|
Octamer Transcription Factor-1 | 1 | 2009 | 17 | 0.090 |
Why?
|
Pyrimidines | 1 | 2012 | 370 | 0.090 |
Why?
|
Neurosecretory Systems | 1 | 2009 | 35 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 1958 | 0.090 |
Why?
|
Gadolinium | 1 | 2009 | 103 | 0.090 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2009 | 6 | 0.090 |
Why?
|
Placebos | 1 | 2009 | 218 | 0.080 |
Why?
|
Enzyme Inhibitors | 3 | 2008 | 632 | 0.080 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2009 | 62 | 0.080 |
Why?
|
MAP Kinase Kinase 4 | 2 | 2008 | 67 | 0.080 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 125 | 0.080 |
Why?
|
Nuclear Receptor Coactivator 3 | 1 | 2008 | 5 | 0.080 |
Why?
|
Amino Acid Sequence | 2 | 2006 | 2062 | 0.080 |
Why?
|
Lactams, Macrocyclic | 1 | 2008 | 14 | 0.080 |
Why?
|
Protein-Energy Malnutrition | 1 | 1988 | 5 | 0.080 |
Why?
|
Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 8 | 0.080 |
Why?
|
Benzoquinones | 1 | 2008 | 27 | 0.080 |
Why?
|
Receptors, Retinoic Acid | 1 | 2008 | 45 | 0.080 |
Why?
|
Histone Acetyltransferases | 1 | 2008 | 38 | 0.080 |
Why?
|
Recombinant Proteins | 2 | 2017 | 1014 | 0.080 |
Why?
|
Mammary Glands, Human | 1 | 2008 | 22 | 0.080 |
Why?
|
Nitriles | 3 | 2017 | 145 | 0.080 |
Why?
|
Precancerous Conditions | 1 | 2009 | 196 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2010 | 170 | 0.080 |
Why?
|
Social Environment | 2 | 2009 | 188 | 0.080 |
Why?
|
Tumor Burden | 2 | 2020 | 288 | 0.080 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 158 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2017 | 8431 | 0.080 |
Why?
|
Molecular Sequence Data | 2 | 2006 | 3029 | 0.080 |
Why?
|
Reperfusion Injury | 1 | 2008 | 131 | 0.080 |
Why?
|
Kinetics | 2 | 2017 | 1513 | 0.080 |
Why?
|
Antigen-Presenting Cells | 1 | 1988 | 139 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 589 | 0.080 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 3087 | 0.080 |
Why?
|
Mice, Knockout | 2 | 2015 | 1918 | 0.080 |
Why?
|
Conserved Sequence | 1 | 2008 | 210 | 0.080 |
Why?
|
Gene Frequency | 1 | 2009 | 676 | 0.080 |
Why?
|
Receptors, Calcitriol | 1 | 2008 | 129 | 0.070 |
Why?
|
Insulin | 1 | 2012 | 1159 | 0.070 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2006 | 13 | 0.070 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2006 | 13 | 0.070 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 21 | 0.070 |
Why?
|
Phenotype | 3 | 2019 | 2375 | 0.070 |
Why?
|
Lymphatic Metastasis | 1 | 2008 | 480 | 0.070 |
Why?
|
In Situ Nick-End Labeling | 1 | 2006 | 121 | 0.070 |
Why?
|
Catalytic Domain | 1 | 2006 | 156 | 0.070 |
Why?
|
Young Adult | 3 | 2017 | 5961 | 0.070 |
Why?
|
Injections | 2 | 2017 | 109 | 0.070 |
Why?
|
Phenylthiohydantoin | 2 | 2017 | 38 | 0.070 |
Why?
|
Alleles | 1 | 2009 | 1127 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 1 | 2006 | 314 | 0.070 |
Why?
|
Trans-Activators | 1 | 2008 | 429 | 0.070 |
Why?
|
DNA Primers | 1 | 2006 | 542 | 0.070 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2004 | 8 | 0.070 |
Why?
|
Base Sequence | 1 | 2009 | 2329 | 0.070 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 68 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 74 | 0.060 |
Why?
|
Benzamides | 2 | 2017 | 226 | 0.060 |
Why?
|
Blotting, Northern | 1 | 2004 | 256 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 113 | 0.060 |
Why?
|
Survival Rate | 2 | 2019 | 1856 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2006 | 679 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 101 | 0.060 |
Why?
|
Genes, Reporter | 1 | 2004 | 266 | 0.060 |
Why?
|
Male | 6 | 2021 | 40860 | 0.060 |
Why?
|
Mice, Nude | 2 | 2017 | 790 | 0.060 |
Why?
|
Age Factors | 1 | 2008 | 1842 | 0.060 |
Why?
|
Liver | 1 | 2008 | 1229 | 0.060 |
Why?
|
DNA | 1 | 2009 | 1293 | 0.060 |
Why?
|
Estrogen Receptor Modulators | 1 | 2003 | 10 | 0.060 |
Why?
|
Epidermal Growth Factor | 1 | 2003 | 119 | 0.060 |
Why?
|
Benzopyrans | 1 | 2003 | 20 | 0.060 |
Why?
|
Tissue Plasminogen Activator | 1 | 2004 | 162 | 0.060 |
Why?
|
Propionates | 1 | 2003 | 34 | 0.060 |
Why?
|
Estrogen Antagonists | 1 | 2003 | 47 | 0.060 |
Why?
|
Thiophenes | 1 | 2003 | 48 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2004 | 360 | 0.060 |
Why?
|
Computational Biology | 1 | 2006 | 528 | 0.060 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2002 | 53 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2003 | 120 | 0.050 |
Why?
|
Multienzyme Complexes | 1 | 2002 | 64 | 0.050 |
Why?
|
Cysteine Endopeptidases | 1 | 2002 | 87 | 0.050 |
Why?
|
Genetic Variation | 1 | 2009 | 1349 | 0.050 |
Why?
|
Molecular Structure | 1 | 2003 | 287 | 0.050 |
Why?
|
Thyroid Neoplasms | 1 | 2006 | 406 | 0.050 |
Why?
|
Psychophysiology | 1 | 2021 | 8 | 0.050 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2004 | 276 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 2 | 2018 | 1214 | 0.050 |
Why?
|
Transcriptional Activation | 1 | 2002 | 280 | 0.050 |
Why?
|
Oncogene Addiction | 1 | 2021 | 2 | 0.050 |
Why?
|
Piperidines | 1 | 2003 | 181 | 0.050 |
Why?
|
Saccharomyces cerevisiae | 1 | 2004 | 434 | 0.050 |
Why?
|
Growth Substances | 1 | 2001 | 80 | 0.050 |
Why?
|
Indoles | 1 | 2003 | 318 | 0.050 |
Why?
|
Hormones | 1 | 2021 | 140 | 0.050 |
Why?
|
Models, Statistical | 1 | 2004 | 574 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 2350 | 0.050 |
Why?
|
Liver Transplantation | 1 | 2008 | 1263 | 0.050 |
Why?
|
Microscopy, Fluorescence | 2 | 2014 | 424 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 2267 | 0.050 |
Why?
|
Fatty Acid Desaturases | 1 | 2000 | 17 | 0.050 |
Why?
|
Regional Blood Flow | 1 | 2020 | 197 | 0.050 |
Why?
|
Computer Simulation | 1 | 2004 | 1077 | 0.050 |
Why?
|
fas Receptor | 1 | 2000 | 75 | 0.050 |
Why?
|
Risk | 1 | 2021 | 673 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 363 | 0.040 |
Why?
|
DNA Damage | 1 | 2021 | 362 | 0.040 |
Why?
|
Cell Membrane | 1 | 2002 | 664 | 0.040 |
Why?
|
DNA Repair | 1 | 2021 | 356 | 0.040 |
Why?
|
Risk Factors | 3 | 2021 | 5397 | 0.040 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 329 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 1208 | 0.040 |
Why?
|
Troleandomycin | 1 | 2017 | 3 | 0.040 |
Why?
|
Cancer Survivors | 1 | 2019 | 85 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 5 | 0.040 |
Why?
|
Glucuronides | 1 | 2017 | 34 | 0.040 |
Why?
|
Ketoconazole | 1 | 2017 | 25 | 0.040 |
Why?
|
Fructose | 1 | 2018 | 35 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2017 | 43 | 0.040 |
Why?
|
Microsomes, Liver | 1 | 2017 | 49 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2017 | 71 | 0.040 |
Why?
|
Weaning | 1 | 2017 | 25 | 0.040 |
Why?
|
bcl-2-Associated X Protein | 1 | 1997 | 47 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2003 | 1168 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 476 | 0.040 |
Why?
|
Adiposity | 1 | 2017 | 70 | 0.040 |
Why?
|
Remission Induction | 2 | 2011 | 722 | 0.040 |
Why?
|
Substrate Specificity | 1 | 2017 | 347 | 0.040 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1997 | 80 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 373 | 0.040 |
Why?
|
Mitoxantrone | 1 | 1996 | 68 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2006 | 1680 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 1997 | 408 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 1671 | 0.040 |
Why?
|
Etoposide | 1 | 1996 | 196 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2017 | 222 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2017 | 356 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 1996 | 192 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 346 | 0.030 |
Why?
|
Cellular Senescence | 1 | 1995 | 94 | 0.030 |
Why?
|
Alternative Splicing | 1 | 1996 | 201 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 237 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 1996 | 199 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2018 | 1015 | 0.030 |
Why?
|
Metribolone | 1 | 2014 | 5 | 0.030 |
Why?
|
Androgen Receptor Antagonists | 1 | 2014 | 18 | 0.030 |
Why?
|
Cisplatin | 1 | 1996 | 612 | 0.030 |
Why?
|
Survival Analysis | 1 | 2018 | 1536 | 0.030 |
Why?
|
Signal-To-Noise Ratio | 1 | 2014 | 94 | 0.030 |
Why?
|
Cell Division | 1 | 1995 | 696 | 0.030 |
Why?
|
Benzoates | 1 | 2014 | 44 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 808 | 0.030 |
Why?
|
Registries | 1 | 2017 | 702 | 0.030 |
Why?
|
Perfusion | 1 | 2014 | 202 | 0.030 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 76 | 0.030 |
Why?
|
Immunoblotting | 1 | 2014 | 267 | 0.030 |
Why?
|
ROC Curve | 1 | 2015 | 752 | 0.030 |
Why?
|
RNA Interference | 1 | 2014 | 368 | 0.030 |
Why?
|
Image Enhancement | 1 | 2016 | 563 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2014 | 615 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 663 | 0.020 |
Why?
|
Interinstitutional Relations | 1 | 2010 | 28 | 0.020 |
Why?
|
United States | 2 | 2017 | 6637 | 0.020 |
Why?
|
Endocrine Glands | 1 | 2009 | 13 | 0.020 |
Why?
|
Corticosterone | 1 | 2009 | 35 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2011 | 206 | 0.020 |
Why?
|
Health Services Research | 1 | 2010 | 135 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2010 | 121 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2009 | 133 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2010 | 174 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2012 | 7949 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2015 | 2699 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2011 | 315 | 0.020 |
Why?
|
Ovary | 1 | 2009 | 250 | 0.020 |
Why?
|
Risk Assessment | 1 | 2016 | 2253 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1988 | 71 | 0.020 |
Why?
|
Recurrence | 1 | 2011 | 1137 | 0.020 |
Why?
|
Microscopy | 1 | 2008 | 87 | 0.020 |
Why?
|
Ovalbumin | 1 | 1988 | 109 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 1988 | 305 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1988 | 158 | 0.020 |
Why?
|
Spleen | 1 | 1988 | 430 | 0.020 |
Why?
|
Behavior, Animal | 1 | 2009 | 373 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2008 | 751 | 0.020 |
Why?
|
Pilot Projects | 1 | 2009 | 837 | 0.020 |
Why?
|
Radiodermatitis | 1 | 2005 | 10 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 1988 | 727 | 0.020 |
Why?
|
Chronic Disease | 1 | 1988 | 968 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2008 | 380 | 0.020 |
Why?
|
Arousal | 1 | 2005 | 170 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 297 | 0.020 |
Why?
|
Butadienes | 1 | 2003 | 33 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 801 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2003 | 24 | 0.010 |
Why?
|
Mammaplasty | 1 | 2005 | 104 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1988 | 724 | 0.010 |
Why?
|
Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
Wound Healing | 1 | 2005 | 342 | 0.010 |
Why?
|
Hypertension | 1 | 2011 | 1139 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2008 | 731 | 0.010 |
Why?
|
Quinazolines | 1 | 2003 | 220 | 0.010 |
Why?
|
Phytotherapy | 1 | 2003 | 132 | 0.010 |
Why?
|
Research | 1 | 2003 | 253 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 1988 | 1195 | 0.010 |
Why?
|
Cytokines | 1 | 2003 | 775 | 0.010 |
Why?
|
Oncogene Protein pp60(v-src) | 1 | 1997 | 3 | 0.010 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 1997 | 21 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 1997 | 47 | 0.010 |
Why?
|
Receptors, Growth Factor | 1 | 1997 | 52 | 0.010 |
Why?
|
Androstadienes | 1 | 1997 | 72 | 0.010 |
Why?
|
ras Proteins | 1 | 1997 | 128 | 0.010 |
Why?
|
Exons | 1 | 1996 | 450 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1996 | 927 | 0.010 |
Why?
|